Ultrarush schedule of subcutaneous immunotherapy with modified allergen extracts is safe in paediatric age
10.5415/apallergy.2016.6.1.35
- Author:
Mário MORAIS-ALMEIDA
1
;
Cristina ARÊDE
;
Graça SAMPAIO
;
Luis Miguel BORREGO
Author Information
1. Allergy Center, CUF Descobertas Hospital, 1998-018 Lisbon, Portugal. mmoraisalmeida@netcabo.pt
- Publication Type:Original Article
- Keywords:
Adverse Events;
Allergens;
Allergoids;
Immunotherapy;
Pediatrics;
Safety
- MeSH:
Allergens;
Appointments and Schedules;
Asthma;
Child;
Conjunctivitis, Allergic;
Dermatitis, Atopic;
Glutaral;
Humans;
Immunotherapy;
Mites;
Pediatrics;
Pollen;
Polymers;
Premedication;
Rhinitis
- From:
Asia Pacific Allergy
2016;6(1):35-42
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Traditional subcutaneous immunotherapy up dosing with allergenic extracts has been shown to be associated with frequent adverse reactions. In recent studies it has been demonstrated that using modified extracts, namely allergoids, it is a safe and effective procedure particularly on accelerated schedules. However data assessing its safety in paediatric age is scarce. OBJECTIVE: To evaluate the safety profile in paediatric population of using modified allergen extracts, in an ultrarush schedule, to reach the maintenance dose in the first day. METHODS: We included children undergoing treatment with subcutaneous immunotherapy during a five-year period, using modified aeroallergen extracts, depigmented, polymerized with glutaraldehyde and adsorbed on aluminium hydroxide using an ultrarush induction phase. The type of adverse reactions during the ultrarush protocol was recorded. RESULTS: We studied 100 paediatric patients (57 males) with a mean age of 11.6 years (5 to 18 years; standard deviation, 3.3), all with moderate to severe persistent rhinitis, with or without allergic conjunctivitis, asthma and atopic eczema, sensitized to mites and/or pollens. All reached the maintenance dose of 0.5 mL in the first day, except 1 child. During the ultrarush protocol the total number of injections was 199. There were 21 local adverse reactions in 11 patients, 11 immediate and 10 delayed; from those, had clinical relevance 1 immediate and 4 delayed. Systemic reactions were recorded in 2 cases, both immediate and mild. CONCLUSION: The ultrarush protocol, without premedication, was a safe alternative to be used in paediatric age during the induction phase of subcutaneous immunotherapy using allergoid depigmented extracts.
